96 related articles for article (PubMed ID: 23607633)
41. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
42. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
[TBL] [Abstract][Full Text] [Related]
43. Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
Kosmidis P; Mylonakis N; Fountzilas G; Samantas E; Athanasiadis A; Skarlos D
Semin Oncol; 1996 Dec; 23(6 Suppl 16):68-70. PubMed ID: 9007126
[TBL] [Abstract][Full Text] [Related]
44. Fractionated administration of carboplatin/paclitaxel reduces neurotoxicity in patients with advanced non-small cell lung cancer.
Ishii Y; Fujimoto S; Okazaki K; Miyoshi M; Furihata T; Hase I; Takizawa H; Kikkawa Y; Yamada I; Fukuda T
Anticancer Drugs; 2011 Oct; 22(9):926-32. PubMed ID: 21712706
[TBL] [Abstract][Full Text] [Related]
45. Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
Socinski MA; Clark JA; Halle J; Steagall A; Kaluzny B; Rosenman JG
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-117-S12-122. PubMed ID: 9331135
[TBL] [Abstract][Full Text] [Related]
46. Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Ichikawa M; Suzuki R; Kataoka K; Noda Y; Shindoh J; Matsumoto S; Tanikawa Y; Suzuki K; Baba K; Shindo Y; Kondo M; Imaizumi K; Kume H; Hasegawa Y; Takagi K; Taniguchi H
Lung Cancer; 2010 Sep; 69(3):319-22. PubMed ID: 20053476
[TBL] [Abstract][Full Text] [Related]
47. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
48. Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials.
Muggia FM; Vafai D; Natale R; Israel V; Zaretsky S; McRae A; Rogers M; Jeffers S
Semin Oncol; 1995 Aug; 22(4 Suppl 9):63-6. PubMed ID: 7644931
[TBL] [Abstract][Full Text] [Related]
49. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
[TBL] [Abstract][Full Text] [Related]
50. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
51. The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer.
Kicken MP; Kilinc HD; Cramer-van der Welle CM; Houterman S; van den Borne BEEM; Smit AAJ; van de Garde EMW; Deenen MJ;
Cancer Treat Res Commun; 2023; 34():100676. PubMed ID: 36592497
[TBL] [Abstract][Full Text] [Related]
52. Toxicity and effectiveness of carboplatin in obese or overweight patients.
Grueso Cuesta C; Poquet Jornet JE; Gasent Blesa JM; Valdivia Perez A; Carrera Hueso FJ; Moreno Royo L
J Oncol Pharm Pract; 2019 Sep; 25(6):1328-1335. PubMed ID: 30086680
[TBL] [Abstract][Full Text] [Related]
53. Effect of Obesity on Hematotoxicity Induced by Carboplatin and Paclitaxel Combination Therapy in Patients with Gynecological Cancer.
Ando Y; Hayashi T; Shiouchi H; Tanaka C; Ito K; Nishibe S; Miyata N; Horiba R; Yanagi H; Fujii T; Kawada K; Ikeda Y; Yamada S
Biol Pharm Bull; 2020 Apr; 43(4):669-674. PubMed ID: 32037352
[TBL] [Abstract][Full Text] [Related]
54. Hematological toxicity of carboplatin for gynecological cancer according to body mass index.
Gutierrez F; Gonzalez-de-la-Fuente GA; Nazco GJ; Oramas J; Batista N
Eur J Clin Pharmacol; 2016 Sep; 72(9):1083-9. PubMed ID: 27287195
[TBL] [Abstract][Full Text] [Related]
55. Myelosuppression by chemotherapy in obese patients with gynecological cancers.
Kamimura K; Matsumoto Y; Zhou Q; Moriyama M; Saijo Y
Cancer Chemother Pharmacol; 2016 Sep; 78(3):633-41. PubMed ID: 27485538
[TBL] [Abstract][Full Text] [Related]
56. High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients.
Lv Y; Ding XS; Li Y; An X; Miao LY
Cancer Biomark; 2016; 16(1):89-97. PubMed ID: 26835709
[TBL] [Abstract][Full Text] [Related]
57. Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer.
Lote H; Sharp A; Redana S; Papadimitraki E; Capelan M; Ring A
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):597-603. PubMed ID: 26936608
[TBL] [Abstract][Full Text] [Related]
58. Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy.
Fujiwara Y; Kiura K; Hotta K; Tabata M; Takigawa N; Tanimoto M
Lung Cancer; 2007 Mar; 55(3):343-8. PubMed ID: 17140694
[TBL] [Abstract][Full Text] [Related]
59. Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer.
Kamiya K; Yamauchi H; Ohtsuki M
Eur J Dermatol; 2020 Oct; 30(5):609-611. PubMed ID: 32972909
[No Abstract] [Full Text] [Related]
60. Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: a case report.
Morichika D; Sato-Hisamoto A; Hotta K; Takata K; Iwaki N; Uchida K; Minami D; Kubo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 May; 44(5):501-5. PubMed ID: 24646812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
